Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antivenom could save lives in remote areas

NCT ID NCT07659002

Disease control Sponsor: Medecins Sans Frontieres, Netherlands Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 600 people in Ethiopia who receive a new type of snakebite antivenom called Premium-PANAF. The antivenom is freeze-dried, so it does not need refrigeration, making it easier to use in remote clinics. Researchers want to see if it safely stops the effects of snake venom and helps patients recover.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Premium-PANAF polyvalent snake antivenom
What this could lead to
If this antivenom proves safe and effective, it could become a standard treatment for snakebites in resource-limited areas, saving many lives.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Allergic reactions or lack of effectiveness are possible risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients presenting to Abdurafi health centre in Northwest Ethiopia with snakebite envenoming from June 2025 - June 2026.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Snakebite envenoming patients who receive Premium-PANAF antivenom * Patients who have given written informed consent . Exclusion criteria * Snakebite envenoming patients who do not receive Premium-PANAF antivenom * Patients referred from other centres who already received other antivenom treatment * Patients who are unable or unwilling to give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Snake envenomation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Snake Bites snakebite envenomation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Snake envenomation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Abdurafi Health Center

    RECRUITING

    Ābderafī, Amhara, Ethiopia

More trials for these conditions

Other studies related to the condition(s) this trial covers.